MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21

Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib

(2019) Melania Poratti et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

CDK4/6 Inhibitors in Combination With Hormone Therapy for HR + /HER2 − Advanced Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials

(2018) Yunfu Deng et al.   Clinical Breast Cancer

Dual Inhibition of CDK4 and CDK2 via Targeting p27 Tyrosine Phosphorylation Induces a Potent and Durable Response in Breast Cancer Cells

(2018) Priyank Patel et al.   MOLECULAR CANCER RESEARCH

In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2–CDK4/6 Targeting and mTOR–S6 Resistance Mechanisms

(2018) Jessica L.F. Teh et al.   Cancer Discovery

A Preexisting Rare PIK3CA E545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling

(2018) Gabriele Romano et al.   Cancer Discovery

Preclinical evaluation of ribociclib and its synergistic effect in combination with alpelisib in non-keratinizing nasopharyngeal carcinoma

(2018) Chi-Hang Wong et al.   Scientific Reports

New Insights into Protein Kinase B/Akt Signaling: Role of Localized Akt Activation and Compartment-Specific Target Proteins for the Cellular Radiation Response

(2018) Klaudia Szymonowicz et al.   Cancers

Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas

(2017) Audrey Laroche-Clary et al.   Journal of Hematology & Oncology

RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1

(2017) S-H Chen et al.   ONCOGENE

MDM2 Antagonists Counteract Drug-Induced DNA Damage

(2017) Anna E. Vilgelm et al.   EBioMedicine

Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors

(2016) Shom Goel et al.   CANCER CELL

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer

(2016) Maria Teresa Herrera-Abreu et al.   CANCER RESEARCH

A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas

(2016) J. R. Infante et al.   CLINICAL CANCER RESEARCH

Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance

(2016) P. Chen et al.   MOLECULAR CANCER THERAPEUTICS

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors

(2016) A. Patnaik et al.   Cancer Discovery

Implications of Genetic and Epigenetic Alterations of CDKN2A (p16 INK4a ) in Cancer

(2016) Ran Zhao et al.   EBioMedicine

Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6

(2015) E. K. Ziemke et al.   CLINICAL CANCER RESEARCH

Treatment of NRAS-Mutant Melanoma

(2015) Douglas B. Johnson et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment

(2015) Anna E. Vilgelm et al.   JNCI-Journal of the National Cancer Institute

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

(2015) Richard S Finn et al.   LANCET ONCOLOGY

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

The PI3K-PKB/Akt Pathway

(2015) Brian A. Hemmings et al.   Cold Spring Harbor Perspectives in Biology

Targeting CDK4 and CDK6: From Discovery to Therapy

(2015) C. J. Sherr et al.   Cancer Discovery

Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment

(2015) Anna E. Vilgelm et al.   JNCI-Journal of the National Cancer Institute

Combined therapies that induce senescence and stabilize p53 block melanoma growth and prompt antitumor immune responses

(2015) Anna Vilgelm et al.   OncoImmunology

CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors

(2014) Sadhna R. Vora et al.   CANCER CELL

Mdm2 and Aurora Kinase A Inhibitors Synergize to Block Melanoma Growth by Driving Apoptosis and Immune Clearance of Tumor Cells

(2014) A. E. Vilgelm et al.   CANCER RESEARCH

The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation

(2014) V. Yadav et al.   MOLECULAR CANCER THERAPEUTICS

Loss ofCDKN2Aexpression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines

(2014) Richard J. Young et al.   Pigment Cell & Melanoma Research

Cyclin-dependent kinases as therapeutic targets in melanoma

(2014) David M. Miller et al.   Pigment Cell & Melanoma Research

Cyclin-dependent kinases

(2014) Marcos Malumbres   GENOME BIOLOGY

Restoring p53 Function in Human Melanoma Cells by Inhibiting MDM2 and Cyclin B1/CDK1-Phosphorylated Nuclear iASPP

(2013) Min Lu et al.   CANCER CELL

The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma

(2013) K. E. Sheppard et al.   CLINICAL CANCER RESEARCH

Preparation of (−)-Nutlin-3 Using Enantioselective Organocatalysis at Decagram Scale

(2013) Tyler A. Davis et al.   JOURNAL OF ORGANIC CHEMISTRY

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

(2013) J. Gao et al.   Science Signaling

Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma

(2012) Lawrence N Kwong et al.   NATURE MEDICINE

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

(2012) Jeffrey A. Sosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cyclin-dependent kinase 1 (Cdk1) is essential for cell division and suppression of DNA re-replication but not for liver regeneration

(2012) M. K. Diril et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

MAP Kinase Pathways

(2012) D. K. Morrison   Cold Spring Harbor Perspectives in Biology

A Systematic Screen for CDK4/6 Substrates Links FOXM1 Phosphorylation to Senescence Suppression in Cancer Cells

(2011) Lars Anders et al.   CANCER CELL

Multiple faces of FoxM1 transcription factor

(2011) Tanya V. Kalin et al.   CELL CYCLE

Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer

(2011) K. T. Flaherty et al.   CLINICAL CANCER RESEARCH

WIPI1 Coordinates Melanogenic Gene Transcription and Melanosome Formation via TORC1 Inhibition

(2011) Hsiang Ho et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Four faces of cellular senescence

(2011) Francis Rodier et al.   JOURNAL OF CELL BIOLOGY

p53 Rescue through HDM2 Antagonism Suppresses Melanoma Growth and Potentiates MEK Inhibition

(2011) Zhenyu Ji et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

E2F1-dependent oncogenic addiction of melanoma cells to MDM2

(2011) M Verhaegen et al.   ONCOGENE

mTOR Signaling

(2011) M. Laplante et al.   Cold Spring Harbor Perspectives in Biology

Transcriptional role of cyclin D1 in development revealed by a genetic–proteomic screen

(2010) Frédéric Bienvenu et al.   NATURE

Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure

(2010) J L Dean et al.   ONCOGENE

Cdk2 and Cdk4 Activities Are Dispensable for Tumorigenesis Caused by the Loss of p53

(2009) V. C. Padmakumar et al.   MOLECULAR AND CELLULAR BIOLOGY

Cyclin-dependent kinases: a family portrait

(2009) Marcos Malumbres et al.   NATURE CELL BIOLOGY

Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources

(2009) Da Wei Huang et al.   Nature Protocols

p21 Inhibits Cdk1 in the Absence of Cdk2 to Maintain the G1/S Phase DNA Damage Checkpoint

(2007) Ande Satyanarayana et al.   MOLECULAR BIOLOGY OF THE CELL